Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1

Interventions

Lenalidomide 6carfilzomib 3Dexamethasone 3daratumumab 2Melphalan 2Leflunomide 2poly ICLC 1pembrolizumab 1isatuximab 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Myelography 1Metformin 1Cyclophosphamide 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Smoldering Multiple Myeloma × Cholestyramine Resin × Clear all
NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡